STOCK TITAN

Stereotaxis Ord Stock Price, News & Analysis

STXS NYSE

Company Description

Overview

Stereotaxis Ord (STXS) is a globally recognized company specializing in innovative robotic technologies designed to elevate the treatment of arrhythmias and perform complex endovascular procedures. With patented robotic navigation systems, the company has enabled physicians to deliver treatment with unmatched precision and safety. Stereotaxis integrates cutting-edge hardware with sophisticated software solutions, positioning itself as a key player in the medical robotics industry and interventional laboratory space.

Core Business Areas

Stereotaxis focuses on the discovery, development, and delivery of advanced robotic systems, instruments, and integrated information solutions. These systems are designed to help interventional physicians achieve:

  • Robotic Precision: By incorporating robotic precision in navigation, the company enhances the accuracy of arrhythmia treatment and endovascular procedures.
  • Enhanced Safety: The engineering behind the systems is intended to improve patient safety by minimizing procedural risks.
  • Lab Efficiency: The innovation in integrated information solutions and technology ensures a streamlined workflow within interventional laboratories.

Industry and Market Context

Operating at the intersection of medical technology and robotics, Stereotaxis stands out in an increasingly competitive market. The company has built a robust portfolio with more than 100 issued patents, supporting its technological edge. Its systems have achieved regulatory clearance across major markets including the United States, European Union, Japan, Canada, and China, further cementing its reputation as an innovator in the field of healthcare technology. Key industry-specific terms such as "robotic navigation," "interventional technology," and "advanced healthcare robotics" underscore its profound expertise in this specialized niche.

Competitive Positioning and Business Model

The company primarily generates revenue through the sale of its proprietary robotic systems and associated instruments, alongside licensing its technology to various interventional laboratories. Stereotaxis differentiates itself through its commitment to innovation and rigorous adherence to regulatory standards. This commitment is supported by a comprehensive patent portfolio that serves as a testament to its continuous research and development efforts. The business model is underpinned by the objective of delivering efficient, reliable, and technologically advanced solutions that enhance patient care and procedural outcomes.

Operational Integration and Technological Innovation

Stereotaxis is dedicated to the integration of state-of-the-art technology within clinical environments. The company’s robotic systems are designed to integrate seamlessly with procedural information infrastructure, thereby enhancing overall lab productivity and decision-making. Emphasizing the role of advanced information solutions, the company supports clinical teams by ensuring that critical data is readily accessible during procedures, which maximizes both precision and workflow efficiency.

Global Reach and Regulatory Achievement

A significant strength of Stereotaxis is its global footprint. Through extensive regulatory clearances in leading markets, the company has established a strong regulatory and commercial presence. The company's ability to navigate and comply with diverse healthcare regulations underscores its commitment to quality and safety, ensuring that its innovations meet stringent international standards.

Commitment to Excellence and Patient Care

Stereotaxis underscores its mission of enhancing patient care through technological excellence. By equipping medical professionals with advanced robotic systems, the company helps achieve superior clinical outcomes. Its focus on safety, precision, and efficient operational integration not only improves procedural performance but also contributes to setting new benchmarks in the field of interventional medicine.

This comprehensive overview paints a clear picture of Stereotaxis Ord as an innovator in the realm of healthcare robotics, offering detailed insights into the company’s business model, product integrity, and market positioning.

Stock Performance

$1.98
+0.51%
+0.01
Last updated: April 27, 2025 at 16:01
21.93 %
Performance 1 year
$159.1M
Market Cap
86.0M
Shares outstanding

SEC Filings

No SEC filings available for Stereotaxis Ord.

Financial Highlights

$26,918,000
Revenue (TTM)
-$24,045,000
Net Income (TTM)
-$0.30
Diluted EPS (TTM)
-$8,497,000
Operating Cash Flow
-89.33%
Net Profit Margin
-91.91%
Oper. Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of Stereotaxis Ord (STXS)?

The current stock price of Stereotaxis Ord (STXS) is $1.97 as of April 25, 2025.

What is the market cap of Stereotaxis Ord (STXS)?

The market cap of Stereotaxis Ord (STXS) is approximately 159.1M.

What is the revenue (TTM) of Stereotaxis Ord (STXS) stock?

The trailing twelve months (TTM) revenue of Stereotaxis Ord (STXS) is $26,918,000.

What is the net income of Stereotaxis Ord (STXS)?

The trailing twelve months (TTM) net income of Stereotaxis Ord (STXS) is -$24,045,000.

What is the earnings per share (EPS) of Stereotaxis Ord (STXS)?

The diluted earnings per share (EPS) of Stereotaxis Ord (STXS) is -$0.30 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Stereotaxis Ord (STXS)?

The operating cash flow of Stereotaxis Ord (STXS) is -$8,497,000.

What is the profit margin of Stereotaxis Ord (STXS)?

The net profit margin of Stereotaxis Ord (STXS) is -89.33%.

What is the operating margin of Stereotaxis Ord (STXS)?

The operating profit margin of Stereotaxis Ord (STXS) is -91.91%.

What is the gross margin of Stereotaxis Ord (STXS)?

The gross profit margin of Stereotaxis Ord (STXS) is 54.22%.

What is the current ratio of Stereotaxis Ord (STXS)?

The current ratio of Stereotaxis Ord (STXS) is 1.22, indicating the company's ability to pay short-term obligations.

What is the gross profit of Stereotaxis Ord (STXS)?

The gross profit of Stereotaxis Ord (STXS) is $14,594,000 on a trailing twelve months (TTM) basis.

What is the operating income of Stereotaxis Ord (STXS)?

The operating income of Stereotaxis Ord (STXS) is -$24,739,000.

What is the primary focus of Stereotaxis Ord?

Stereotaxis Ord specializes in developing innovative robotic systems for treatment of arrhythmias and performing endovascular procedures, enhancing both precision and patient safety.

How does Stereotaxis generate revenue?

The company generates revenue primarily through the sale and licensing of its proprietary robotic systems, instruments, and integrated information solutions to interventional laboratories.

What sets Stereotaxis apart in the medical robotics industry?

Its commitment to technological innovation, a robust portfolio of issued patents, and extensive regulatory clearances in major global markets distinguishes Stereotaxis from its competitors.

How does the company improve lab efficiency?

Through the integration of advanced robotic systems with sophisticated information solutions, Stereotaxis enhances procedural workflows and supports clinical decision-making in interventional laboratories.

What industries benefit from Stereotaxis’ technologies?

Stereotaxis primarily serves the healthcare sector, particularly interventional cardiology and radiology, by providing systems that improve the accuracy, safety, and efficiency of medical procedures.

How widespread is the regulatory clearance of Stereotaxis systems?

The company's systems have received regulatory clearance in key markets such as the United States, European Union, Japan, Canada, and China, ensuring the platforms meet high quality and safety standards.